Feasibility study of paclitaxel plus carboplatin in patients with endometrial cancer: A Japan Kanto Tumor Board study (JKTB trial). Issue 1 (28th May 2012)

• Record Type: Journal Article
• Authors: Yamada, Kyosuke; Tanabe, Hiroshi; Imai, Manami; Jobo, Toshiko; Kudo, Kazuya; Fujiwara, Hiroyuki; Nagata, Chie; Furuya, Kenichi; Suzuki, Mitsuaki; Ochiai, Kazunori; Tanaka, Tadao; Yasuda, Makoto
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 39:Issue 1(2013:Jan.)
• Page Start: 311
• Page End: 316
• Publication Date: 2012-05-28
• Subjects: Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/j.1447-0756.2012.01890.x
• Languages: English
• ISSNs: 1341-8076

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p> <bold>Aim: </bold> The optimal chemotherapy regimen for patients with endometrial cancer has not been established. We assessed the feasibility of paclitaxel plus carboplatin (TC) for postoperative chemotherapy in patients with endometrial cancer.</p> <p> <bold>Material and Methods: </bold> Patients with newly diagnosed endometrial cancer received TC (paclitaxel 180 mg/m², carboplatin AUC6 mg/mL/min) every three weeks. Treatment was continued until disease progression or completion of six cycles. Toxicities were evaluated every cycle according to NCI‐CTCAE version 3.0.</p> <p> <bold>Results: </bold> Sixty patients were registered from December 2005 through November 2006. Forty‐four of 60 (73.3%) cases completed all of the planned six cycles. Grades 3 and 4 hematologic toxicities were observed as follows: leukopenia (61.7%), neutropenia (95.0%), anemia (21.7%), and thrombocytopenia (5.0%). There were six patients who dropped out from the protocol by neutropenia. Grade 3 non‐hematologic toxicities were observed as follows: nausea (3.3%), vomiting (1.7%), neuropathy (5.0%), myalgia (6.7%) and constipation (1.7%). No grade 4 non‐hematologic toxicity was observed.</p> <p> <bold>Conclusion: </bold> This TC regimen is feasible for endometrial cancer patients.</p> </abstract>